|
| ||||||||||||||||||||||||||||||
| ![]() | ![]() Pfizer Takes 12% of Perlegen SciencesPress Release December 28, 2005 LOS ANGELES, CA, (NAMC) – On Tuesday, Perlegen Sciences, Inc. made the announcement that Pfizer Inc (NYSE: PFE) has invested over $50 million in Perlegen, taking approximately twelve (12) percent of the co mpany. Pfizer and Perlegen entered into their first research collaboration in December 2002, using Perlegen's DNA sample preparation, high resolution SNP genotyping, and data analysis capabilities to discover genes associated with common diseases and identify genetic markers that may predict patient response to medicines. Perlegen Sciences co-founder and CEO, Brad Margus, said "We all recognize the challenges and risks that drug discovery and development poise. Industry-wide, many new drugs have been discontinued in late-stage trials, after hundreds of millions of dollars have been invested. Many times this results because a subset of patients responded differently from the rest." Michael Rossi Business News Correspondent NAMC Newswire www.namcnewswire.com
About hireBio
::
Copyright ::
Privacy
:: Legal
:: Contact |
|
|
![]() |